-
1
-
-
4544288090
-
Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose
-
Zhao F, Loke C, Rankin SC, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76:210-219.
-
(2004)
Clin Pharmacol Ther
, vol.76
, pp. 210-219
-
-
Zhao, F.1
Loke, C.2
Rankin, S.C.3
-
2
-
-
24944503322
-
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
-
Yuan HY, Chen JJ, Lee MTM, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-1751.
-
(2005)
Hum Mol Genet
, vol.14
, pp. 1745-1751
-
-
Yuan, H.Y.1
Chen, J.J.2
Lee, M.T.M.3
-
3
-
-
33646479231
-
CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese
-
Chern HD, Ueng TH, Fu YP, et al. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clin Chim Acta 2006; 367: 108-113.
-
(2006)
Clin Chim Acta
, vol.367
, pp. 108-113
-
-
Chern, H.D.1
Ueng, T.H.2
Fu, Y.P.3
-
4
-
-
18244400400
-
Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?
-
You JHS, Chan FWH, Wong RSM, et al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59: 582-587.
-
(2005)
Br J Clin Pharmacol
, vol.59
, pp. 582-587
-
-
You, J.H.S.1
Chan, F.W.H.2
Wong, R.S.M.3
-
5
-
-
0022997648
-
Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship
-
Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504.
-
(1986)
Clin Pharmacokinet
, vol.11
, pp. 483-504
-
-
Holford, N.H.G.1
-
6
-
-
0028149598
-
Stereochemical aspects of warfarin drug interactions. Use of a combined pharmacokinetic-pharmacodynamic model
-
Chan E, McLachlan A, O'Reilly R, et al. Stereochemical aspects of warfarin drug interactions. Use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994; 56: 286-294.
-
(1994)
Clin Pharmacol Ther
, vol.56
, pp. 286-294
-
-
Chan, E.1
McLachlan, A.2
O'Reilly, R.3
-
7
-
-
0036085787
-
Genetic polymorphisms in assessing interindividual variability in delivered dose
-
Haber LT, Maier A, Gentry PR, et al. Genetic polymorphisms in assessing interindividual variability in delivered dose. Reg Toxicol Pharmacol 2002; 35: 177-197.
-
(2002)
Reg Toxicol Pharmacol
, vol.35
, pp. 177-197
-
-
Haber, L.T.1
Maier, A.2
Gentry, P.R.3
-
8
-
-
25144502325
-
Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
-
Veenstra DL, You JHS, Rieder MJ, et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15: 687-691.
-
(2005)
Pharmacogenet Genomics
, vol.15
, pp. 687-691
-
-
Veenstra, D.L.1
You, J.H.S.2
Rieder, M.J.3
-
9
-
-
0035078166
-
Development and validation of a sensitive and robust LC-tandem MS method for the analysis of warfarin enantiomers in human plasma
-
Naidong W, Ring PR, Midtlien C, et al. Development and validation of a sensitive and robust LC-tandem MS method for the analysis of warfarin enantiomers in human plasma. J Pharm Biomed Anal 2001; 25: 219-226.
-
(2001)
J Pharm Biomed Anal
, vol.25
, pp. 219-226
-
-
Naidong, W.1
Ring, P.R.2
Midtlien, C.3
-
10
-
-
0031807762
-
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
-
Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-528.
-
(1998)
Clin Pharmacol Ther
, vol.63
, pp. 519-528
-
-
Takahashi, H.1
Kashima, T.2
Nomizo, Y.3
-
11
-
-
0037374422
-
Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients
-
Takahashi H, Wilkinson G, Caraco Y, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-263.
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 253-263
-
-
Takahashi, H.1
Wilkinson, G.2
Caraco, Y.3
-
12
-
-
1842526962
-
5′-Flanking region polymorphisms of CYP2C9 and their relationship, to S-warfarin metabolism in white and Japanese patients
-
Takahashi H, Ieiri I, Wilkinson GR, et al. 5′-Flanking region polymorphisms of CYP2C9 and their relationship, to S-warfarin metabolism in white and Japanese patients. Blood 2004; 103: 3055-3057.
-
(2004)
Blood
, vol.103
, pp. 3055-3057
-
-
Takahashi, H.1
Ieiri, I.2
Wilkinson, G.R.3
-
13
-
-
31344451857
-
Different contributions of polymorphism in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
-
Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphism in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 10 1-110.
-
(2006)
Pharmacogenet Genomics
, vol.16
, Issue.10
, pp. 1-110
-
-
Takahashi, H.1
Wilkinson, G.R.2
Nutescu, E.A.3
-
14
-
-
23044440450
-
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirement: Proposal for a new dosing regimen
-
Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirement: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
-
(2005)
Blood
, vol.106
, pp. 2329-2333
-
-
Sconce, E.A.1
Khan, T.I.2
Wynne, H.A.3
-
15
-
-
1542346414
-
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
-
Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004; 75: 204-212.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 204-212
-
-
Kamali, F.1
Khan, T.I.2
King, B.P.3
-
16
-
-
0029123928
-
The influence of age, liver size and enantiomer concentrations on warfarin requirements
-
Wynne H, Cope L, Kelly P, et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Pharmacol 1995; 40: 203-207.
-
(1995)
Br J Pharmacol
, vol.40
, pp. 203-207
-
-
Wynne, H.1
Cope, L.2
Kelly, P.3
-
17
-
-
0036914221
-
Influence of CYP2C9 and CYP2C19 genetic polymorphism on warfarin maintenance dose and metabolic clearance
-
Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphism on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-710.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 702-710
-
-
Scordo, M.G.1
Pengo, V.2
Spina, E.3
|